Press release
Migraine Drugs Market Share, Trends, Size, Research and Forecast 2019-2025
A full report of Global Migraine Drugs Market is available at: https://www.omrglobal.com/industry-reports/migraine-drugs-market
Some of the strategies that are majorly being adopted by these players include new products offering, expansion, partnership & collaboration, and mergers & acquisitions among others. For instance, Allergan's Ubrogepant and Eli Lilly's Lasmiditan are the migraine drugs based on the advanced mechanism of action.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/migraine-drugs-market
In February 2020, Biohaven Pharmaceutical Holding Co. Ltd.’s oral pill known as Nurtec ODT, chemically known as rimegepant was approved by the US FDA. This drug is consumed for dismissing the pain after the onset of migraine headaches. The dug falls under CGRP and directly competes with the first approved Allergan Plc’s Ubrelvy.
In December 2019, the migraine drug Ubrogepant (Ubrelvy) manufactured by Allergen Plc has been approved by the US FDA. Ubrogepant is the CGRP drug in tablet form which is meant to be taken immediately after the onset of migraines by adults.
In September 2018, Ajovy, a migraine drug manufactured by Teva Pharmaceutical Industries Ltd. received US regulatory approval. Ajovy is an injectable drug that is to be taken in a few months for relieving migraines in adults.
In May 2018, Aimovig, the drug manufactured by Amgen Inc. received the US FDA approval. The drug is given monthly by self-injection and charges up to $575 monthly in the US. The company manufactured Aimovig in partnership with Novartis International AG, a Swiss multinational pharmaceutical company.
Current Market Trends Covered in the Global Migraine Drug Market Report:
• Increased healthcare spending and improving healthcare infrastructure is influencing the global migraine drugs industry growth during the forecast period.
• Shifting consumer preferences towards the use of injections for a quicker relief is expected to provide ample growth opportunities for market growth.
• The injection segment will account for significant growth in the market.
• The novel drug innovations, various regulatory approvals, and geographical expansions will be the key strategy of the players.
• North America region is expected to hold a prominent share in the migraine drugs market.
Global Migraine Drugs Market – Segmentation
By Type
• Acute Migraine Treatment
• Preventive Migraine Treatment
By Route of Administration
• Oral
• Injectable
• Others (Spray)
For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/migraine-drugs-market
Global Migraine Drugs Market – Segmentation by Region
North America
• United States
• Canada
Europe
• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America
Company Profiles
• Allergan Plc
• Amgen Inc.
• Astrazeneca PLC
• Bausch Health Companies Inc.
• Biohaven Pharmaceutical Holding Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly & Co.
• GlaxoSmithKline Plc
• H. Lundbeck A/S
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Mylan N.V.
• Novartis International AG
• Neurelis, Inc.
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceuticals Industries Ltd.
• Upsher-Smith Laboratories, Inc.
• Zosanos Pharma Corp.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 7803040404
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit https://www.omrglobal.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine Drugs Market Share, Trends, Size, Research and Forecast 2019-2025 here
News-ID: 2122879 • Views: …
More Releases from Orion Market Research
AI-Enabled Imaging Modalities Market Rising Demand and Growth Forecast Through 2 …
AI-enabled imaging modalities market was valued at approximately USD 1.36 billion, and it is projected to reach around USD 19.78 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 34.67% from 2024 to 2033.
AI-Enabled Imaging Modalities Market Overview
The AI-enabled imaging modalities market is experiencing rapid growth, driven by advancements in artificial intelligence and machine learning technologies. These innovations are enhancing the capabilities of various imaging modalities, including…
Tumor Tracking Systems Market Size Analysis, Competitive Insights, Leading Playe …
Global tumor tracking systems market was valued at approximately USD 3.5 billion, and it is projected to reach around USD 6.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 5% from 2024 to 2033.
Tumor Tracking Systems Market Overview
The tumor tracking systems market is experiencing steady growth, driven by the increasing incidence of cancer and advancements in imaging and tracking technologies. These systems improve the precision of…
Tumor Tracking Systems Market Size Future Scope, Demands and Projected Industry …
Tumor tracking systems market was valued at approximately USD 3.5 billion, and it is projected to reach around USD 6.6 billion by 2033, reflecting a compound annual growth rate (CAGR) of about 5% from 2024 to 2033.
Tumor Tracking Systems Market Overview
The tumor tracking systems market is experiencing steady growth, driven by the increasing prevalence of cancer and advancements in imaging technologies. These systems play a crucial role in enhancing the…
SNP genotyping Market Size Analysis, Competitive Insights, Leading Players and G …
SNP genotyping market was valued at approximately USD 31.66 billion, and it is projected to reach around USD 238.25 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 20.1% from 2024 to 2034.
SNP genotyping Market Overview
The SNP genotyping market is experiencing significant growth, driven by advancements in genotyping technologies, an increase in the prevalence of genetic disorders, and the expansion of pharmacogenomics and precision medicine initiatives. This…
More Releases for Migraine
Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share?
The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market?
The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes.
Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR…
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market.
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive…
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which…
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases.
The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs.
Get Access to TOC /…
